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“Is the veteran alive of deceased?” The database does not
contain any information on what caused the death. We have
proposed looking at the National Death Index, which is avail-
able via linkage with Social Security numbers to determine cause
of death. However, the problem even with this data set is that,
for determining aneurysm-related death, autopsy rates are so
low that a lot of assumptions are made and speculations on what
is the cause of death, so we decided to only analyze all-cause
mortality.
Dr Sicard. And since this is a data set that is very robust in risk
adjustments, did you do any univariate or multivariate analysis to
identify what were those risk factors that could predict or that have
an association with mortality?
Dr Bush. In this particular study, we did not. In our first
study, now published in the Journal of the American College of
Surgeons, we looked at the endovascular versus open repair in all
elective cases listed in the NSQIP database. In this study we looked
at factors that may be independent predictors of outcome. We
found that advanced age, especially over 80, was associated with
mortality as was a history of stroke, smoking, and liver disease. And
we created a separate variable for hospital volume. In this study,
low-volume hospitals, in univariate analysis, were predictive of
mortality. However, in our multivariate analyses, this variable was
not significant.
Dr Sicard. Again, congratulations, and I hope all the mem-
bers that are here will attend this Saturday’s session because we will
be looking at different levels of evidence exactly on this issue of
high-risk patients.
Dr Robert Cambria (Bangor, Me). I had a simple question
about the definition of high risk. Looking at your slides, I don’t
think I see any low-risk patients based on those criteria. How
many procedures were excluded, both in the EVAR and open
category, for not being high risk, if you have that information?
Dr Bush. I do. During the time frame we looked at, fromMay
2001 through December 2004, there were about 3400 elective
aneurysm repairs performed at that time in VA hospitals. Of these,
2400 patients fit our high-risk criteria. We found that in our first
study, again, when we looked at the whole cohort together,
probably 75% of our patients in that original cohort could be
identified as a high risk, so we made the definition fairly strict for
this study. VA patients have been suggested to have more comor-
bidities and this may account for our relatively high-risk population
overall.
Dr George Geroulakos (London, United Kingdom). I won-
der whether you considered that perhaps the population of high
risk, as you defined it, is not entirely comparable to the EVAR 2;
therefore, you cannot draw the conclusion that is written in the
abstract that high-risk patients could be considered safely, or
relatively safely, for intervention. To give you an example, you said
that a history of coronary artery bypass graft was considered as one
of the risk factors that makes patients to belong to the high-risk
group; while, in fact, what we’re trying to do is to convert these
high-risk factors to low-risk factors. So if a patient had coronary
artery bypass grafts and remained asymptomatic, he would not be
considered anymore, as far as risk factor is concerned, to a high-risk
group.
Dr Bush. You are absolutely right. One of the problems with
looking at administrative databases is, indeed, what is the defini-
tion of the variables being entered into the database as well as the
consistency of data entry? Furthermore, the data entry relies on the
people that are putting in the data. For example, a patient who is
undergoing coronary revascularization, or has had this procedure,
may or may not be completely now symptom-free or free from
coronary disease after their bypass.
The NSQIP database, it is a robust validated database. The
data are being entered by trained nurse abstractors who are con-
tinually audited by the Department of Veteran Affairs, and they
have strict definitions of actually what goes into the database. So
it’s more than just ICD-9 codes within that database.
But you are correct, I do not know if the patients are symptom-
free or still symptomatic following their coronary revascularization.
Dr Michel Makaroun (Pittsburgh, Pa). To my knowledge,
this is probably the first time I see a long-term survival curve from
all-cause mortality with a significant advantage of the endovascular
group over the open group long term. And I did not even see the
early separation in the first year that is very typical of these curves.
Do you have an explanation why your results are so different than
the usual analysis of one versus the other?
Dr Bush. That’s a very good point, and we did see our
patients demonstrating a benefit of endovascular repair and we
also saw that in all the patients as well, not just those that fit our
high-risk criteria. With the BIRLS database, we had death
information on almost every patient. We found that very few
patients had unavailable information. So our number of patients
at risk at the beginning is the same as the number of patients at
the end of the 2 years who are at risk. So it may be part of the
lack of data censorship in our survival curves that makes this
difference.
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The treatment of infrarenal aortic aneurysm (AAA) in the
high-risk patient remains a challenge. The clinical introduction
of endovascular aneurysm repair (EVAR) offers the benefits of a
less invasive technique that was originally intended to expand
treatment to patients previously deemed not surgical candi-
dates.
During the last decade, many single-center and registry
series have consistently demonstrated a perioperative mortality
and morbidity benefit of EVAR compared with conventional
open repair (COR). Subgroup analyses of the high-risk patient
cohorts have shown a similar benefit of EVAR over COR. What
have been missing from the literature are uniformity, objectiv-
ity, and a precise definition of what constitutes a high-risk
patient. Scoring systems have been proposed for COR, but in
general, they do not apply to high-risk patients.1 Furthermore,
none of the scoring systems for high-risk patients treated with
EVAR have been validated.
A recently published randomized clinical trial of high-risk
patients (EVAR 2) comparing EVAR with medical follow-up
showed a high perioperative mortality (9%) in the treatment arm
and no survival advantage at 4 years between EVAR and the
medical follow-up arm.2 Some concerns have been raised about
whether the results of this randomized clinical trial should be
extrapolated to all “unfit-for-surgery” AAA patients. A high mor-
tality in the EVAR randomized group and a lowmortality of EVAR
in the no-treatment group who crossed over to EVAR has raised
questions about the validity of the conclusions in this trial.
Bush and colleagues evaluate the results of EVAR versus
COR in the high-risk patients in the National Surgical Quality
Improvement Program, a large, national, validated, highly au-
dited database. The lower 30-day and 1-year all-cause mortality
in the EVAR compared with the COR group concurs with the
recently published Society for Vascular Surgery Outcomes
Committee’s analysis of the high-risk patients in the investiga-
tional device exemption United States Food and Drug Admin-
istration EVAR trials.3 Bush and colleagues attempt to further
stratify the results of the high-risk population by separately
analyzing the American Society of Anesthesiologists class 4
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subgroup. Although not statistically significant, EVAR also
demonstrated a perioperative and 1-year survival benefit over
open repair.
Most investigators agree that some high-risk patients do not
benefit from either COR or EVAR. The objective identification of
those patients remains a great challenge, primarily because of the
many variables to consider. The international vascular community
should come together to establish and validate a scoring system
with objective definitions that reproducibly predict outcomes in
high-risk patients with AAA.
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